Two coronavirus vaccine candidates enter human trials, 60 in pre-clinical stage: WHO


Two candidate vaccines for COVID-19 have entered the first phase of human clinical trials and another 60 candidate vaccines are in pre-clinical studies, the World Health Organisation (WHO) has confirmed.

The vaccine candidate jointly developed by CanSino Biological Inc and Beijing Institute of Biotechnology uses the non-replicating viral vector as the platform, same as the non-corona candidates like Ebola, to develop a vaccine with a 'Adenovirus Type 5' candidate, a draft landscape of COVID-19 vaccine candidates brought out today.

Sources say adenoviruses are common viruses that cause pneumonia and can deliver potential antigens to stimulate the production of antibodies that work against the disease. CanSino Biological Inc, in association with the Chinese Academy of Military Medical Science's Bioengineering Institute, had developed an Ebola vaccine in 2017.

The other vaccine that has entered the first phase of trials is from the US-based biotech firm Moderna and the National Institute of Allergy and Infectious Diseases (NIAID) combine. This lipid nanoparticle (LNP) encapsulated mRNA candidate vaccine uses an RNA platform with multiple candidates. In this, the virus's genetic information is de-coded from the DNA to make proteins. mRNA, or messenger RNA, acts as an intermediary between the genetic information in DNA and the amino acid sequence of proteins, which gives cells command to make proteins that fight the viruses. But such vaccines have not yet been approved for human use, said sources.

As reported earlier, India's Zydus Cadila, Serum Institute and Bharat Biotech are among the global firms working on COVID-19 vaccine. The WHO update says 60 vaccine candidates are in the pre-clinical trial stage. Experts believe it will take 12 to 18 months before a vaccine is available. Normally, the vaccine candidate, from the pre-clinical stage, which includes testing in small and large animals, have to go through three phases of clinical trials to prove its safety and efficacy. These human trials are done on different population in various geographies and have to create huge data in the 3 phases of human trials for regulatory sanctions. In emergencies like this, fast tracking is possible, but the vaccine candidates still have to go through various trials before being introduced in the market. Typically, only one in ten experimental vaccines make it all the way through to regulatory approval.

A standard editorial manager system is utilized for manuscript submission, review, editorial processing and tracking which can be securely accessed by the authors, reviewers and editors for monitoring and tracking the article processing. Manuscripts can be uploaded online at Editorial Tracking System ( or forwarded to the Editorial Office at:

 How we work:

  • After submission, an acknowledgement with manuscript number is sent to the corresponding author within 7 working days.
  • A 21 day window time frame is allotted for peer-review process wherein multiple experts are contacted.
  • Author proof is generated within 7 working days after the acceptance decision.

Benefits on Publication:

Open Access: Permanent free access to your article upon publication ensures extensive global reach and readership.

Easy Article Sharing: Our open access enables you to share your article directly with colleagues through email and on social media via a single link, permitting third party reuse with appropriate citation in addition to the retention of content copyright by the author.

Global Marketing: Through promotion in a targeted global email announcement or press release, your article will be seen by thousands of the top-most thought-leaders in your field.

Color Art: In a world of black & white journal articles, high-quality full-color images make your article stand out from the crowd and tell a complete story, increasing readers and citations.

Social Media Exposure: Extended reach for your article through links on Twitter accounts provides maximum visibility worldwide.

Reprints: Distribute your work to colleagues and at conferences as we provide hard copy color reprints of your article on order.

Media Contact:
Sarah Eve | Journal Manager
Journal of Pharmaceutical Sciences and Drug Development
Whatsapp No:  +1-504-608-2390